Back to Search
AMIR RAHEMTULLA, M.D.
M.D.
Clinical Pathology/Laboratory Medicine Physician
NPI: 1639146426Individual
Specialties, Licenses & Credentials
Clinical Pathology/Laboratory Medicine PhysicianPrimary
Pathology — Clinical Pathology/Laboratory Medicine
Code: 207ZP0105X
152016(MA)
Research & Publications (20)
Immunophenotype of neoplastic plasma cells in AL amyloidosis.
PMID 19638544·J Clin Pathol·2009
8-other
Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.
PMID 17526802·J Clin Pathol·2008
8-other
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
PMID 17115062·Bone Marrow Transplant·2007
8-other
Multiple myeloma with bone marrow extracellular crystal deposition.
PMID 17496192·J Clin Pathol·2007
5-case
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
PMID 17361226·Leukemia·2007
8-other
Images in cardiovascular medicine. Intermittent loss of second heart sound.
PMID 17130350·Circulation·2006
5-case
Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation.
PMID 16646053·Int J Cancer·2006
8-other
The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
PMID 16822294·Br J Haematol·2006
4-observational
Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation.
PMID 16967191·Clin Res Cardiol·2006
5-case
Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis.
PMID 16565738·Bone Marrow Transplant·2006
8-other
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
PMID 16081156·Leuk Res·2006
5-case
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
PMID 16501593·Bone Marrow Transplant·2006
8-other
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
PMID 17107351·Br J Haematol·2006
8-other
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.
PMID 16079895·Leukemia·2005
3-trial
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
PMID 16191086·Eur J Haematol·2005
4-observational
Human invariant NKT cells are required for effective in vitro alloresponses.
PMID 16210612·J Immunol·2005
8-other
Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
PMID 16227683·Acta Haematol·2005
8-other
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
PMID 16263571·Leuk Lymphoma·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 81 HIGHLAND AVE, PATHOLOGY DEPARTMENT
SALEM, MA 01970 - Phone
- (978) 354-4161
Quick Facts
- NPI
- 1639146426
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile